Towards Healthcare
Respiratory Drugs Market Size Increases to $30.81 Bn by 2034

Respiratory Drugs Market Size, Key Players & Emerging Treatments

According to forecasts, the global respiratory drugs market will grow from USD 17.53 billion in 2024 to USD 30.81 billion by 2034, with an expected CAGR of 5.8%. In 2023, COPD was the most common respiratory disorder, leading the market with a 36% share. Bronchodilators dominated treatment options with a 40% share. Hospital pharmacies were the top distribution channel, playing a key role in delivering respiratory medications to patients.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Respiratory Drugs Market Assessment

  • Overview
  • Global Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Lung Cancer
    • Respiratory Tract Infection
    • Allergic Rhinitis
    • Cystic Fibrosis (CF)
    • Others
  • Global Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Bronchodilators
    • Corticosteroids
    • Combination Drugs
    • Antibiotics
    • Target Therapy
    • Immunotherapy
    • CFTR
    • Others
  • Global Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Nasal
    • Injectable
  • Global Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

North America Respiratory Drugs Market Assessment

  • Overview
  • North America Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Lung Cancer
    • Respiratory Tract Infection
    • Allergic Rhinitis
    • Cystic Fibrosis (CF)
    • Others
  • North America Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Bronchodilators
    • Corticosteroids
    • Combination Drugs
    • Antibiotics
    • Target Therapy
    • Immunotherapy
    • CFTR
    • Others
  • North America Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Nasal
    • Injectable
  • North America Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Europe Respiratory Drugs Market Assessment

  • Overview
  • Europe Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Lung Cancer
    • Respiratory Tract Infection
    • Allergic Rhinitis
    • Cystic Fibrosis (CF)
    • Others
  • Europe Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Bronchodilators
    • Corticosteroids
    • Combination Drugs
    • Antibiotics
    • Target Therapy
    • Immunotherapy
    • CFTR
    • Others
  • Europe Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Nasal
    • Injectable
  • Europe Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Asia Pacific Respiratory Drugs Market Assessment

  • Overview
  • Asia Pacific Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Lung Cancer
    • Respiratory Tract Infection
    • Allergic Rhinitis
    • Cystic Fibrosis (CF)
    • Others
  • Asia Pacific Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Bronchodilators
    • Corticosteroids
    • Combination Drugs
    • Antibiotics
    • Target Therapy
    • Immunotherapy
    • CFTR
    • Others
  • Asia Pacific Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Nasal
    • Injectable
  • Asia Pacific Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Middle East and Africa Respiratory Drugs Market Assessment

  • Overview
  • Middle East and Africa Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Lung Cancer
    • Respiratory Tract Infection
    • Allergic Rhinitis
    • Cystic Fibrosis (CF)
    • Others
  • Middle East and Africa Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Bronchodilators
    • Corticosteroids
    • Combination Drugs
    • Antibiotics
    • Target Therapy
    • Immunotherapy
    • CFTR
    • Others
  • Middle East and Africa Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Nasal
    • Injectable
  • Middle East and Africa Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

South America Respiratory Drugs Market Assessment

  • Overview
  • South America Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Lung Cancer
    • Respiratory Tract Infection
    • Allergic Rhinitis
    • Cystic Fibrosis (CF)
    • Others
  • South America Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Bronchodilators
    • Corticosteroids
    • Combination Drugs
    • Antibiotics
    • Target Therapy
    • Immunotherapy
    • CFTR
    • Others
  • South America Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Nasal
    • Injectable
  • South America Respiratory Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Companies Profile

  • GlaxoSmithKline Plc
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Mylan Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Ltd.

Conclusion & Recommendations

  • Insight Code: 5137
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: March 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

Respiratory disorders affect the lungs, airways, and respiratory muscles, leading to coughing, wheezing, shortness of breath, and chest tightness.

Corticosteroids are crucial in managing respiratory disorders due to their anti-inflammatory properties, which help reduce inflammation in the airways and lungs. By alleviating inflammation, corticosteroids can improve lung function, relieve symptoms like coughing and wheezing, and prevent exacerbations in conditions like asthma and COPD, leading to better overall respiratory health.

One of the hurdles in the respiratory drugs market is the high cost of medications, devices, and healthcare services, which can limit access to care for individuals without adequate insurance coverage or financial resources.

Centers for Disease Control and Prevention, National Institute of Health, World Health Organization, National Cancer Institute, MedlinePlus.gov., Forum of International Respiratory Societies.